Clinical trial

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

NCT05815186

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2024-04-01

PhasePHASE2

Study timeline

Study start (estimated)2024-04-01Date precision: month

Registry last updated2024-03-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutationunresolved

Interventions

SotorasibDRUG · verified · RxNorm: sotorasib

LadarixinDRUG

Sponsors & collaborators

NYU Langone Healthlead sponsor

Mapped research locations

New YorkNew York, United States3 New Hyde ParkNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05815186 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.